FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk
THURSDAY, Feb. 13, 2020 -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S....
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Diets | Food and Drug Administration (FDA) | General Medicine | Nutrition | Weight Loss